Naringenin for Health & Longevity
Evidence Review created on 10/08/2026 using AI4L + evidence-mcp / Sonnet 5.5
Also known as: Naringetol, Salipurpol, 4’,5,7-Trihydroxyflavanone, 5,7,4’-Trihydroxyflavanone
Motivation
Naringenin is a compound found in grapefruit, oranges and other citrus fruit, and in tomatoes. In citrus it occurs mostly bound to a sugar as naringin, and bacteria in the gut release the free form. Interest in naringenin as a supplement comes from its proposed influence on metabolism and cellular aging.
Laboratory and animal studies have examined naringenin in relation to cholesterol, blood glucose and brain aging. Small human trials have given doses of a few hundred milligrams daily as purified capsules or orange extract, whereas citrus fruit and juice supply far less. The compound also drew attention through research on why grapefruit juice changes the levels of some medications.
This review examines what human and animal evidence exists for naringenin as a longevity-oriented supplement, how strong that evidence is, what is known about safety and drug interactions, and which doses and monitoring approaches have been used in studies. It is written for health- and longevity-oriented adults who weigh potential benefits against uncertainty.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
Narrative reviews that give a high-level view of naringenin, selected for direct relevance.
-
The Therapeutic Potential of Naringenin: A Review of Clinical Trials - Salehi et al., 2019
Narrative review of human naringenin studies, mainly bioavailability (the share of a dose absorbed into the blood) and cardiovascular trials in participants with overweight or high cholesterol; sets out the clinical evidence available before 2019.
-
Narrative review of laboratory and animal evidence tying naringenin to brain-aging processes such as mitochondrial function and oxidative stress; entirely preclinical.
-
Strategies for enhancing the bioavailability of naringenin: A comprehensive review - Akkuzu et al., 2026
Explains why naringenin is poorly absorbed and how cyclodextrin complexes, nanoparticles and other delivery systems address this; relevant for interpreting supplement doses.
No dedicated naringenin overview was located from Peter Attia, Andrew Huberman, Chris Kresser or Life Extension Magazine (which mentions naringenin only in passing within articles on other topics); FoundMyFitness and Lifespan.io offer only short items on single mouse studies. The list therefore reflects the three qualifying sources found.
Grokipedia
AI-generated encyclopedia entry covering chemistry, citrus sources, reported bioactivities and low oral bioavailability; it notes that most effects come from preclinical models.
Examine
Examine overview (updated August 2025) summarizing mostly animal and laboratory cell evidence for antioxidant, anti-inflammatory and heart-protective effects, with a research feed of newer studies.
ConsumerLab
No ConsumerLab article on naringenin exists.
Systematic Reviews
Systematic reviews and meta-analyses (formal pooling of study results) of naringenin on PubMed, most of which pool animal or cell studies rather than human trials.
-
A Comprehensive Systematic Review of the Effects of Naringenin, a Citrus-Derived Flavonoid, on Risk Factors for Nonalcoholic Fatty Liver Disease - Naeini et al., 2021
Reviews 36 mostly preclinical studies on fatty liver disease (excess liver fat); concludes that human trials were lacking.
-
Naringenin induces intrinsic and extrinsic apoptotic signaling pathways in cancer cells: A systematic review and meta-analysis of in vitro and in vivo data - Faramarzi et al., 2022
Pools 32 cell and animal studies; naringenin raised markers of programmed cancer-cell death. No human data.
-
The effect of immunomodulatory properties of naringenin on the inhibition of inflammation and oxidative stress in autoimmune disease models: a systematic review and meta-analysis of preclinical evidence - Alimohammadi et al., 2022
Pools 12 animal studies: naringenin lowered inflammatory and oxidative-stress markers in autoimmune models. Clinical trials were excluded.
-
Effects of Naringenin on Diabetic Nephropathy: A Systematic Review and Meta-Analysis of Rodent Studies - Qu et al., 2026
Pools 12 rodent studies: naringenin lowered blood glucose, urinary protein and kidney oxidative-stress markers in diabetic kidney disease models.
-
Antidepressant effects and therapeutic potential of naringenin: a systematic review and meta-analysis of preclinical studies - Huang et al., 2026
Pools 13 rat studies: naringenin reduced depression-like behavior; the authors state all evidence is animal-derived.
Every listed paper concerns naringenin alone and rests largely on preclinical data. No systematic review or meta-analysis of naringenin’s adverse effects, or of its human clinical trials specifically, was found on PubMed, so the principal risk (drug interactions) and the human efficacy evidence are unrepresented; naringenin appears only as one subgroup in a broader polyphenol (plant compound class) meta-analysis in fatty liver disease (Yang et al., 2022).
Mechanism of Action
Naringenin is the aglycone (sugar-free form) of naringin, the sugar-bound compound abundant in grapefruit. Gut bacteria release the free form, which the intestine and liver largely attach to glucuronic acid or sulfate (conjugation), so free levels are low (Akkuzu et al., 2026, review). In humans, serum levels peak about 2.4–3.2 hours after oral doses of 150–600 mg, the half-life (time for the blood level to halve) is roughly 3 hours, and exposure rises in proportion to dose (Rebello et al., 2020). Liver enzymes of the cytochrome P450 family 1 (CYP1; enzymes that oxidize many compounds) also metabolize it (Nagayoshi et al., 2023).
Proposed actions are broad rather than selective. In human adipocytes (fat cells), naringenin acts through PPAR (peroxisome proliferator-activated receptors, which regulate fat metabolism) to raise UCP1 (a heat-producing protein) (Murugesan et al., 2020). In animals it activates SIRT1 (an enzyme linked to cellular aging) (Wang et al., 2023), dampens MAPK (an inflammation signaling pathway) in the brain, where it crosses the blood-brain barrier (Zhu et al., 2024), while in cell-based binding assays it binds estrogen receptors, preferring the beta subtype (Kuiper et al., 1998).
A competing view questions relevance: although the 8 micromolar concentration effective in human adipocytes is below the total serum peak after 150 mg (15.8 micromolar; Rebello et al., 2020), most circulating naringenin is probably conjugated, so the free fraction may be far lower (an inference, not measured).
Historical Context & Evolution
Naringenin first drew attention as the breakdown product of naringin, the bitter sugar-bound compound of grapefruit. In the 1990s, grapefruit juice was found to raise blood levels of several oral drugs, and naringin became a leading suspect (Fuhr & Kummert, 1995). Later work shifted the explanation: whole grapefruit raised felodipine exposure about threefold, with furanocoumarins (other grapefruit compounds) driving much of the enzyme inhibition and naringenin acting only competitively in laboratory enzyme tests (Bailey et al., 2000), while naringin proved a selective inhibitor of OATP1A2 (an intestinal uptake transporter) (Bailey et al., 2007).
Health interest then moved to naringenin itself. Cell and rodent work on cholesterol lowering, glucose handling and antiviral activity (Shulman et al., 2011) led to a pilot in seven people with hepatitis C (a viral liver infection; NCT01091077, completed 2013, no results posted). Human plasma kinetics were first described from juice (Erlund et al., 2001), and a controlled single-dose study of a purified orange extract followed in 2020 (Rebello et al., 2020). Longevity interest rests on 2020s findings in roundworms and mice (Piragine et al., 2024); lifespan has not been tested in mammals, and the current evidence base may change as controlled human data accrue.
Expected Benefits
High 🟩 🟩 🟩
Blood Lipid Profile
In a randomized, placebo-controlled trial of 44 overweight or obese adults with non-alcoholic fatty liver disease (NAFLD; liver fat unrelated to alcohol), naringenin 100 mg twice daily for 4 weeks lowered triglycerides, total cholesterol and LDL (low-density lipoprotein, an atherogenic carrier) cholesterol and raised HDL (high-density lipoprotein, a protective carrier) cholesterol versus placebo (Namkhah et al., 2021). The same cohort showed lower atherogenic indices (cholesterol ratios) (Naeini et al., 2022). An independent Jilin group reported better lipid patterns than placebo in 95 osteosarcoma surgery patients (Zhang et al., 2018).
Magnitude: Versus placebo after 4 weeks (200 mg/day, 44 participants): lower triglycerides (P < 0.001), total cholesterol (P = 0.01) and LDL cholesterol (P = 0.02), and higher HDL cholesterol (P = 0.02) (P is the probability that a difference this large arises by chance; below 0.05 is conventionally called significant). In the osteosarcoma trial (20 mg/day), lipid patterns were better than with placebo at 16 and 24 months (P < 0.05) but not at 8 months. The abstracts and results text reviewed give P values but no between-group differences, so no outcome figure is available.
Medium 🟩 🟩
Liver Fat Grade in Fatty Liver Disease
The same Tehran trial reported fewer participants in higher NAFLD grades (degrees of liver fat) with naringenin than with placebo, while liver enzymes and a fibrosis (liver scarring) score were unchanged (Namkhah et al., 2021). The evidence is a single 4-week trial, and the grading method and effect sizes are not given in the abstract.
Magnitude: NAFLD grade percentages were lower than with placebo (P < 0.001); liver enzymes and the fibrosis score did not differ significantly. The abstract reports no between-group figures, so no outcome figure is available.
Osteosarcoma Recurrence After Surgery ⭕️ Not Central to Health & Longevity
In 95 people who had undergone surgery for osteosarcoma (a bone cancer), naringenin 20 mg daily versus placebo, followed for about two years in a study the full text describes as randomized, was reported with smaller tumor volumes, a lower recurrence rate and lower reactive oxygen species (unstable oxygen molecules) (Zhang et al., 2018). Blinding is not described, and no replication exists. This bears on cancer-treatment research, not prevention.
Magnitude: Versus placebo after about 2 years: local recurrence 38.3% vs 73.0% (P < 0.01) and mean tumor volume (± standard deviation, the spread of individual values) 106.3 ± 92.7 vs 225.8 ± 141.4 cm³ (P < 0.05); reactive oxygen species were lower with naringenin (P < 0.05). The source reports no confidence intervals (CI; ranges likely to contain the true effect).
Low 🟩
Body Weight and Visceral Fat ⚠️ Conflicted
Body mass index (BMI; weight relative to height) and visceral fat level (fat around internal organs) fell versus placebo after 4 weeks in a pilot trial (Naeini et al., 2022). A 6-month juice trial found no such change (Habauzit et al., 2015). Net: unreplicated; juice supplied sugar-bound naringenin.
Magnitude: Versus placebo, lower BMI (P = 0.001) and visceral fat level (P = 0.039); systolic blood pressure marginally lower but not significant (P = 0.055). The abstract reports no between-group differences, so no outcome figure is available.
Arterial Stiffness
In a 6-month randomized crossover trial (each participant received both drinks), 48 postmenopausal women drank 340 mL grapefruit juice daily (210 mg sugar-bound naringenin) or a flavanone-free drink (flavanones: citrus flavonoids); aortic stiffness was lower with juice (Habauzit et al., 2015). Evidence is indirect: whole juice with sugar-bound naringenin.
Magnitude: Carotid-femoral pulse wave velocity (aortic stiffness) was 0.34 m/s lower with juice than with the control drink (7.36 vs 7.70 m/s; P = 0.019); the abstract gives no 95% CI.
Endothelial Function ⚠️ Conflicted
Flavanone-rich orange beverages attenuated the post-meal fall in flow-mediated dilatation (artery widening, an endothelial function measure) in 28 healthy men (Rendeiro et al., 2016). A 6-month juice trial found no change (Habauzit et al., 2015). Evidence is indirect (juice, whole orange). Net: acute effect only, none sustained.
Magnitude: Versus a calorie-matched control, flow-mediated dilatation 7 hours after a high-fat double meal was better preserved with each flavanone beverage (P < 0.05), with no larger effect at higher flavanone doses; the abstract reports no between-group figures, so no outcome figure is available.
Insulin Sensitivity and Energy Expenditure ⚠️ Conflicted
One woman with diabetes given 150 mg naringenin three times daily for 8 weeks lost 2.3 kg, with lower insulin (Murugesan et al., 2020). Adipocytes showed impaired insulin response (Richard et al., 2013); a 6-month juice trial found no glucose change (Habauzit et al., 2015). Net: uncontrolled case, contradicted.
Magnitude: No control group (one participant): body weight −2.3 kg, insulin −18% and resting metabolic rate peaking 3.5% above baseline at 1 hour; the glucose change was not clinically significant.
Cognitive Function and Brain Aging ⚠️ Conflicted
Alzheimer’s-model mice showed less plaque and better memory (Zhu et al., 2024). A 36-week randomized trial of a citrus extract containing only 3 mg naringenin found no cognitive benefit over placebo in 80 older adults (Galluzzi et al., 2024). Net: no human benefit shown, at a far lower dose.
Magnitude: No difference from placebo: total score on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS; a standardized set of memory and thinking tests) rose by 4.63 points with the citrus extract and 5.63 with placebo over 36 weeks (within-group changes, not compared between groups); the group-by-time interaction (whether the change over time differed between groups) was not significant (P = 0.910).
Speculative 🟨
Lifespan and Cellular Senescence
Naringenin extended lifespan in Caenorhabditis elegans roundworms (Piragine et al., 2024) and reduced vascular senescence markers (signs of aged, non-dividing cells) in atherosclerosis-prone mice (artery plaque buildup) (Wang et al., 2023). Animal evidence only.
Muscle Endurance
Mice fed naringenin ran farther and gained grip strength, linked to more endurance-type muscle fibers (Lv et al., 2023). Animal evidence only.
Inflammation and Oxidative Stress ⚠️ Conflicted
An animal meta-analysis found lower inflammatory and oxidative-stress markers (Alimohammadi et al., 2022). Randomized juice and extract trials showed no benefit over control (Habauzit et al., 2015; Galluzzi et al., 2024). Net: animal benefit only.
Bone Health
Naringenin reduced senescence of osteoblasts (bone-forming cells) and improved bone structure in an aging-bone-loss animal model, via estrogen receptors (Kaushal et al., 2026). Human data are pending.
Cancer Cell Death ⭕️ Not Central to Health & Longevity
A meta-analysis of cell and animal studies found raised markers of apoptosis (programmed cell death) in cancer cells (Faramarzi et al., 2022). This bears on cancer-treatment research, not prevention; the meta-analysis included no human data.
Diabetic Kidney Injury ⭕️ Not Central to Health & Longevity
A meta-analysis of 12 rodent studies found lower blood glucose, urinary protein and kidney oxidative-stress markers in diabetic kidney disease models (Qu et al., 2026). This bears on diabetic-complication research; no human data.
Depression-Like Behavior ⭕️ Not Central to Health & Longevity
A meta-analysis of 13 rat studies found less depression-like behavior with naringenin (Huang et al., 2026). This bears on antidepressant research, not longevity; no human data.
Benefit-Modifying Factors
- Genetic variation: No naringenin-specific polymorphism study was found. Activity of OATP1A2 (an intestinal uptake transporter) may differ by genetics (Bailey et al., 2007); the effect on benefit is unproven.
- Individual absorption: Plasma naringenin varied markedly between people and was detectable in only 22% of samples after a high fruit-and-vegetable diet that included citrus (Erlund et al., 2002), so exposure for a given dose may differ widely.
- Baseline biomarkers: Lipid and liver-fat effects were observed in people with fatty liver and metabolic risk (Namkhah et al., 2021); the effect in healthy volunteers remains debatable (Salehi et al., 2019, review).
- Sex: No sex-stratified analysis exists. Naringenin binds estrogen receptors (Kuiper et al., 1998), so hormonal status could modify effects; untested.
- Pre-existing conditions: Controlled efficacy data come from overweight adults with fatty liver (Namkhah et al., 2021) and postmenopausal women (Habauzit et al., 2015); transfer to healthy adults is unproven.
- Age: The one trial in older adults (80 participants, ages 60–75 per NCT04744922) showed no cognitive benefit (Galluzzi et al., 2024); no other efficacy data exist for adults over 65.
Potential Risks & Side Effects
High 🟥 🟥 🟥
No risk reaches High: no human trial from more than one independent group documents an adverse event attributable to naringenin.
Medium 🟥 🟥
No risk reaches Medium: the only controlled human safety data are one single-dose trial and short supplementation trials from one group, which show no excess adverse events and no clinical outcome of harm.
Low 🟥
Non-Serious Adverse Events at Single Doses
In an 18-person randomized crossover trial, single doses of 150–900 mg of orange-extract naringenin produced only non-serious events (abdominal pain, itching, headache, drowsiness, visual disturbance), with no significant difference from placebo, no serious events and no relevant laboratory changes (Rebello et al., 2020). Single-dose exposure says little about chronic use.
Magnitude: Events affected 1–3 of 9 participants at each naringenin dose level versus 4 of 18 on placebo (registry results, NCT03582553); no serious events occurred at any dose, and all events were non-serious.
Reduced Absorption of OATP1A2 Substrate Drugs
Naringin, the sugar-bound parent compound, inhibits OATP1A2, an intestinal transporter that carries some drugs (its substrate drugs) into the body, and lowered oral fexofenadine (an antihistamine) exposure in small randomized crossover trials (Bailey et al., 2007). Evidence is indirect: naringin, not naringenin, at a grapefruit-juice-matching concentration.
Magnitude: Fexofenadine AUC (area under the concentration-time curve, total drug exposure) with naringin solution was 75% of that with water (P < 0.05) and 55% with grapefruit juice (P < 0.001). Clinical outcomes and adverse-event rates were not measured.
QT Prolongation and Cardiac Ion Channel Blockade
Grapefruit juice lengthened the QTc interval (heart-rate-corrected QT, a heart-rhythm measure on an electrocardiogram), most in congenital long QT syndrome (an inherited heart-rhythm disorder) (Piccirillo et al., 2008; Chorin et al., 2019). Naringenin blocked cardiac ion channels in cells (Sanson et al., 2022). Evidence is indirect: juice, not purified naringenin.
Magnitude: Net QTc prolongation after 2 L of grapefruit juice was 14.0 ms (95% CI 6.2–21.7) in 30 healthy volunteers versus off-drug readings, and 21.8 ms (95% CI 3.4–35.3) in 10 patients with congenital long QT syndrome, tested without a control group (Chorin et al., 2019). QT variability index (beat-to-beat variation in QT length) was also higher after pink grapefruit juice than placebo in 32 subjects (P < 0.05; Piccirillo et al., 2008).
Speculative 🟨
CYP3A4 Enzyme Inhibition
Naringenin inhibited CYP3A4 (a liver and gut drug-metabolizing enzyme) competitively in laboratory enzyme assays (Bailey et al., 2000) and raised tofacitinib exposure in rats (Wang et al., 2020). No human naringenin data.
Estrogen Receptor Activity
Naringenin binds estrogen receptors in laboratory binding assays, preferring the beta subtype (Kuiper et al., 1998). Hormonal effects in humans are untested.
Reproductive and Developmental Toxicity at High Doses
EFSA (European Food Safety Authority) reported thymus-weight, litter-size and pup-weight changes at high doses in a toxicity study that could not be dismissed (EFSA evaluation, 2024). No concern at flavouring-level exposure; no human data.
Risk-Modifying Factors
- Genetic variation: No naringenin-specific polymorphism study exists. Variants affecting OATP1A2 activity could modify drug-absorption interactions (Bailey et al., 2007); this is theoretical.
- Baseline biomarkers: Abnormal liver or kidney tests were exclusion criteria in a registered fracture trial (NCT06612762), so risk at abnormal baselines is unstudied.
- Sex: Grapefruit juice lengthened QTc more in female patients (Chorin et al., 2019); the single-dose trial reported no sex-based analysis of adverse events (Rebello et al., 2020).
- Pre-existing conditions: Congenital long QT syndrome (inherited prolongation of the QT interval, a heart-rhythm measure): grapefruit juice lengthened QTc most in affected patients (Chorin et al., 2019). Hormone-sensitive cancers are a theoretical concern (Kuiper et al., 1998).
- Age: No safety data exist beyond healthy adults in single-dose and 4–8 week studies; older-adult safety was balanced with placebo in one 36-week extract trial (Galluzzi et al., 2024).
Key Interactions & Contraindications
Prescription drugs
- OATP substrate drugs (fexofenadine, aliskiren): Caution (theoretical for naringenin). Naringin lowered fexofenadine exposure to 75% of water (Bailey et al., 2007); grapefruit juice also affects aliskiren (Rebello et al., 2012). Consequence: weaker drug effect. Spacing doses by hours is common practice.
- CYP3A4 substrate drugs (drugs it breaks down: felodipine, simvastatin, atorvastatin, tacrolimus, dasatinib): Caution (theoretical for naringenin). Whole grapefruit raised felodipine exposure about threefold, mostly via furanocoumarins (Bailey et al., 2000); naringenin raised dasatinib exposure in rats (Raish et al., 2024). Consequence: higher drug levels.
- QT-prolonging drugs (amiodarone, sotalol, haloperidol, citalopram): Caution (theoretical for purified naringenin). Grapefruit juice lengthened QTc in healthy volunteers (Chorin et al., 2019), and naringenin blocked ion channels in cells (Sanson et al., 2022); this could raise arrhythmia (irregular heartbeat) risk. Baseline electrocardiogram mitigates.
- Glucose-lowering drugs (insulin, metformin, glimepiride): Monitor (theoretical). Lower insulin, with no clinically significant glucose change, appeared in one uncontrolled case (Murugesan et al., 2020); consequence could be hypoglycemia (low blood glucose).
- Lipid-lowering drugs (atorvastatin, rosuvastatin, ezetimibe): Monitor (theoretical). Additive cholesterol lowering is plausible given the fatty-liver trial (Namkhah et al., 2021); statins (cholesterol-lowering drugs) metabolized by CYP3A4 add the exposure concern above. Consequence: excessive lowering or statin muscle toxicity.
- Hormone therapies (tamoxifen, anastrozole, estradiol): Caution (theoretical for purified naringenin). Grapefruit juice (containing sugar-bound naringenin) raised combined estrogen exposure after oral estradiol in women after ovary removal (Schubert et al., 1994); naringenin binds estrogen receptors (Kuiper et al., 1998). Consequence: altered hormone-therapy exposure.
Over-the-counter (OTC) medications
- Fexofenadine (OTC antihistamine): Caution (theoretical for naringenin); see OATP entry above. Consequence is reduced antihistamine effect.
- Other OTC medicines (ibuprofen, acetaminophen, antacids): No interaction identified (severity: none; no clinical consequence expected).
Supplements
- Other lipid- or glucose-lowering supplements (berberine, red yeast rice, niacin): Monitor (theoretical). Additive effects on lipids or glucose are plausible; consequence is excessive lowering.
- Other estrogen-active plant compounds (soy isoflavones, red clover): Monitor (theoretical). Additive estrogen receptor activity is possible; consequence: stronger hormonal effects (theoretical).
- Other CYP3A4 or transporter inhibitors (curcumin with piperine, bergamot, grapefruit extracts): Monitor (theoretical). Additive increases in co-administered drug levels are plausible.
- Other citrus flavonoids (hesperetin, quercetin): Informational (no clinical consequence identified). Given together in a juice mix, naringenin showed higher relative bioavailability than quercetin or hesperetin; the abstract reports no safety finding (Krogholm et al., 2010).
Other interventions
- Probiotics: Informational. Four weeks of a microencapsulated probiotic increased orange-juice flavanone bioavailability in humans, whereas a single acute dose did not (Pereira-Caro et al., 2015); consequence is higher exposure.
- Grapefruit juice and citrus products: Caution. They add naringin and furanocoumarins on top of any supplement (Bailey et al., 2000); consequence is compounded drug-interaction effects.
- High-fat meals: No interaction. A high-fat diet had an insignificant effect on naringin and naringenin kinetics (Bai et al., 2020).
Populations who should avoid Naringenin:
- People using CYP3A4 or OATP substrate drugs with a narrow margin between effective and toxic dose (tacrolimus, dasatinib, fexofenadine, aliskiren) without prescriber review (theoretical).
- Congenital long QT syndrome or use of QT-prolonging drugs (amiodarone, sotalol, haloperidol; grapefruit juice lengthened QTc most in congenital long QT syndrome, Chorin et al., 2019; theoretical for purified naringenin, Sanson et al., 2022).
- Hormone-sensitive cancers such as breast or endometrial cancer (theoretical; estrogen receptor binding).
- Pregnancy and lactation (theoretical): no human safety data were identified, and high-dose reproductive and developmental changes were reported in animals (EFSA evaluation, 2024).
- Advanced kidney failure (blood creatinine above 1.4 mg/dL) or liver cirrhosis (advanced liver scarring) (theoretical): excluded from a registered naringenin trial (NCT06612762); no safety data.
Risk Mitigation Strategies
Doses and timings below follow common practice unless cited.
- Dose within tested range: Single doses of 150–900 mg were tolerated in healthy adults (Rebello et al., 2020); staying within trial-tested amounts mitigates the unknown toxicity of higher chronic exposure.
- Dose separation from OATP substrates: Separating fexofenadine or aliskiren dosing from naringenin or grapefruit products by several hours is common practice and may limit the reduced drug absorption seen with naringin.
- Prescriber or pharmacist review: Review of CYP3A4-dependent drugs (statins, tacrolimus, dasatinib) before starting addresses the risk of raised drug levels.
- Baseline electrocardiogram: One obtained before use alongside QT-prolonging drugs addresses the QT concern from juice and cell data.
- Oncology review: Review by the treating team during hormone-sensitive cancer therapy addresses unexplored estrogen receptor effects.
- Laboratory checks: Liver and kidney tests at baseline and after 4–12 weeks address the lack of chronic-use safety data noted under Non-Serious Adverse Events at Single Doses; abnormal tests led to exclusion in a registered trial (NCT06612762).
- Verified product identity: Products stating naringenin content per capsule limit unintended naringin intake, which inhibits OATP1A2 and reduces drug absorption.
Therapeutic Protocol
Each dose below is cited to its source; other parameters (timing, cycling, titration steps) reflect common practice unless cited.
- Fatty liver trial regimen: 100 mg capsules twice daily, before lunch and dinner, for 4 weeks (Namkhah et al., 2021).
- Higher-dose regimens: 150 mg three times daily for 8 weeks in one participant (Murugesan et al., 2020); 300 mg twice daily was proposed from blood-level data but not tested for efficacy (Rebello et al., 2020).
- Dietary juice route: 340 mL grapefruit juice daily, supplying 210 mg sugar-bound naringenin, for 6 months (Habauzit et al., 2015); sugar-bound form rather than purified naringenin.
- Registered fracture regimen: 500 mg daily for 14 days, then 250 mg daily to day 90 (NCT06612762); results not yet available.
- Originating groups: Pennington Biomedical Research Center (Rebello, Greenway, Coulter; orange extract at 28% naringenin) and Tehran University of Medical Sciences (Namkhah, Naeini; fatty liver trials).
- Time of day: Trials dosed before meals; serum levels were dose-proportional fed or fasted (Rebello et al., 2020). No timing study exists.
- Half-life: About 3.0 hours at 150 mg and 2.65 hours at 600 mg (Rebello et al., 2020); 1.3–2.2 hours from juice (Erlund et al., 2001).
- Single versus split doses: The fatty liver and case-report regimens split the daily dose (twice or three times daily), consistent with the short half-life, whereas the cognition trial used one capsule daily (NCT04744922); no head-to-head comparison exists.
- Genetic variants: No variant has been shown to alter dose response; OATP1A2 activity may vary genetically (Bailey et al., 2007).
- Sex differences: No sex-specific dosing or response data exist.
- Age: Adult trials only; no dose adjustment data for older adults.
- Baseline biomarkers: Lipid responses came from people with fatty liver and elevated metabolic risk (Namkhah et al., 2021); healthy-range baselines are unstudied.
- Pre-existing conditions: Responses are documented only in fatty liver, diabetes (one case) and postmenopausal women; none in other populations.
Discontinuation & Cycling
- Duration: Trials lasted 4 weeks (Namkhah et al., 2021) to 8 weeks (Murugesan et al., 2020); no long-term or lifelong regimen has been studied.
- Withdrawal effects: None documented; the available trials did not report rebound effects, and how long benefits persist after stopping is unknown.
- Tapering: No trial described a taper. The registered fracture trial steps down from 500 to 250 mg daily (NCT06612762), which is a planned dose reduction, not a withdrawal taper.
- Cycling: No evidence supports or refutes cycling; no tolerance to naringenin has been described, so any on-off schedule reflects speculation.
Sourcing and Quality
- Compound identity: Naringenin (free form), naringin (sugar-bound) and citrus extracts differ. Trials used purified capsules (Namkhah et al., 2021) or an orange extract at 28% naringenin with 8.5% naringin (Rebello et al., 2020).
- Content labeling: Labels stating naringenin milligrams per capsule, not only “citrus bioflavonoids,” allow comparison with trial doses.
- Third-party testing: ConsumerLab has not reviewed naringenin products; independent verification of content and contaminants (for example by a certified laboratory) is the usual quality check for supplements.
- Formulation: Cyclodextrin complexation raised naringenin exposure 7.4-fold in rats (Shulman et al., 2011); enhanced formulations have no matching human dose data, so trial doses may not transfer.
- Reputable brands: No independently tested brand was identified; the trial extract was supplied by a commercial manufacturer (Green Chem/Gencor Lifestage Solutions) and analysed at Rutgers University Botanical Centre (Rebello et al., 2020).
Practical Considerations
- Time to effect: Lipid and liver-fat changes appeared within 4 weeks in one trial (Namkhah et al., 2021); no study has measured longevity endpoints, so time to any such effect is unknown.
- Common pitfalls: Confusing naringin with naringenin; extrapolating rodent or roundworm doses; substituting grapefruit juice for a supplement while ignoring furanocoumarin drug interactions; overlooking medication interactions.
- Regulatory status: In the United States, dietary supplements fall under the Dietary Supplement Health and Education Act; manufacturers are responsible for safety and labeling before marketing, and the Food and Drug Administration (FDA) acts after products reach the market (FDA).
Interaction with Foundational Habits
- Sleep: Direction: none established. No controlled sleep study exists; drowsiness occurred in 1 of 9 participants at 300 mg and in none on placebo in the single-dose trial (NCT03582553).
- Nutrition: Direction: indirect. Exposure was dose-proportional fed or fasted (Rebello et al., 2020), and a high-fat diet had an insignificant effect (Bai et al., 2020); four weeks of a probiotic raised flavanone bioavailability, an acute dose did not (Pereira-Caro et al., 2015). Grapefruit products add drug-interaction concerns.
- Exercise: Direction: potentiating in mice only. Naringenin improved running distance and grip strength (Lv et al., 2023); no human exercise trial or timing data exist.
- Stress management: Direction: none established. Rats showed less depression-like behavior (Huang et al., 2026); cortisol or stress-response effects in humans are unstudied.
Monitoring Protocol & Defining Success
Baseline testing before starting covers liver enzymes, kidney function, a lipid panel and fasting glucose and insulin; an electrocardiogram is relevant when QT-prolonging drugs are used, and a medication review covers CYP3A4 and OATP substrates. Ongoing monitoring follows a cadence of 4 weeks, 12 weeks, then every 6–12 months, with the lipid panel and metabolic markers repeated at each point to judge whether the expected changes appeared and the safety markers repeated to confirm stability. Because the trials ran only 4–8 weeks, the longer cadence reflects common practice rather than evidence, and results are best read against the individual’s own baseline, since few sourced optimal ranges exist for these markers.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Alanine aminotransferase and aspartate aminotransferase | Approx. 7–55 U/L and 8–48 U/L (standard reference range) | Safety check: rising values would stop use | Liver enzymes; fasting not required; the fatty liver trial saw no change (Namkhah et al., 2021) |
| Creatinine | 0.6–1.3 mg/dL (standard reference range) | Safety check: kidney function | A registered trial excluded creatinine above 1.4 mg/dL (NCT06612762) |
| LDL cholesterol, triglycerides, HDL cholesterol | No established target; track change from the individual’s own baseline | Expected-change marker: lipid effect in fatty liver trial | Fasting 9–12 hours; improvements seen at 4 weeks (Namkhah et al., 2021) |
| Fasting glucose and insulin | Insulin approx. 2–25 µIU/mL (standard reference range); glucose: no established target, track change from the individual’s own baseline | Expected-change marker: insulin fell 18% in one case | Fasting 8 hours; one uncontrolled case (Murugesan et al., 2020) |
| QTc interval (electrocardiogram) | No established target; track change from the individual’s own baseline | Safety check: relevant with QT-prolonging drugs | QTc is the heart-rate-corrected QT interval; cell data show ion channel block (Sanson et al., 2022) |
Qualitative markers:
- Gastrointestinal tolerance (abdominal pain, nausea)
- Energy level and exercise capacity
- Body weight and waist circumference
- Unusual symptoms of higher drug exposure in people using CYP3A4 or OATP substrate medications
Emerging Research
- Fracture-healing trial: NCT06612762 is a recruiting, placebo-controlled trial with participants, carers and investigators unaware of assignment (70 participants; primary outcomes C-reactive protein and pentraxin 3, both inflammation markers; estimated primary completion 19 October 2026). A positive result would support an anti-inflammatory action in humans; a null result would weaken it at 250–500 mg.
- Completed cognition trial: NCT04744922 (80 older adults, completed 2023, no results posted on the registry) published null results (Galluzzi et al., 2024), weakening the cognition case at 3 mg naringenin; higher-dose trials are absent.
- Completed safety trial: NCT03582553 (18 participants, completed 2018, results posted; academic sponsor with US National Institutes of Health support, no commercial sponsor listed) underlies the single-dose safety data (Rebello et al., 2020).
- Independent replication: The liver-fat finding rests on one group (Yang et al., 2022, meta-analysis found only that trial); an independent randomized trial in fatty liver disease could move that grade toward High, erase it, or show whether the lipid findings hold in this population.
- Mammalian longevity: Roundworm lifespan (Ge et al., 2021) and mouse brain markers (Piragine et al., 2024) lack mammalian lifespan studies; a null mouse lifespan result would weaken the longevity case.
- Senescence and brain-cell renewal: A mouse study linked naringenin to lower TNF-α (an inflammatory protein) and better memory (Gao et al., 2020); human senescence-marker trials do not exist.
- Delivery systems: Cyclodextrin complexes raised exposure in rats (Shulman et al., 2011); reviews list further options (Akkuzu et al., 2026). Human blood-level confirmation could multiply or reduce effective dose needs.
- Safety signals: Animal drug-interaction data (Raish et al., 2024) and ion channel data (Sanson et al., 2022) await a human interaction study, which could weaken the safety case.
Conclusion
Naringenin is a citrus plant compound that is also available as a supplement. The human evidence is small. A few short trials, mostly from one research group in people with fatty liver disease and overweight, report better cholesterol and triglyceride levels and less liver fat; a small separate trial in another patient group also reported better cholesterol levels, but the liver fat finding has not been repeated by independent teams. Other human findings come from juice, from a single case without a comparison group, or from a trial of a very low dose that showed no benefit for thinking skills. Claims about longevity, muscle, bone and brain aging rest on animal and cell studies only, so they remain speculative.
In a small single-dose trial in healthy adults, the events that occurred were minor and similar to placebo. The main concerns are theoretical or indirect: naringin, the sugar-bound form found in citrus, can lower the absorption of some medicines, laboratory data suggest possible effects on how medicines are processed, on heart rhythm and on hormone signaling, and no long-term safety data exist.
The overall evidence base is thin and comes mostly from laboratory and animal work; the main safety trial received public funding, and no dominant commercial sponsor was identified. For health- and longevity-oriented adults, naringenin currently stands as a plausible but unproven candidate for metabolic and aging-related goals, with uncertain effects in people who are already metabolically healthy.